A detailed history of Sjs Investment Consulting Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sjs Investment Consulting Inc. holds 26 shares of NTLA stock, worth $311. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26
Previous 28 7.14%
Holding current value
$311
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$19.72 - $27.36 $39 - $54
-2 Reduced 7.14%
26 $0
Q4 2023

Jan 16, 2024

BUY
$23.16 - $32.34 $23 - $32
1 Added 3.7%
28 $0
Q3 2023

Oct 17, 2023

BUY
$31.62 - $45.78 $63 - $91
2 Added 8.0%
27 $0
Q3 2022

Oct 13, 2022

SELL
$53.92 - $71.7 $10,784 - $14,340
-200 Reduced 88.89%
25 $1,000
Q4 2021

Feb 11, 2022

BUY
$100.76 - $138.36 $22,671 - $31,131
225 New
225 $27,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $910M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Sjs Investment Consulting Inc. Portfolio

Follow Sjs Investment Consulting Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sjs Investment Consulting Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sjs Investment Consulting Inc. with notifications on news.